The National Institutes of Health announced the formation of the international HIV Prevention Trials Network to develop and test promising non-vaccine strategies to prevent the spread of HIV/AIDS. The global initiative will explore alternative measures, besides AIDS vaccines, that may be able to block or reduce infection with HIV. The network will constitute NIH's largest comprehensive multicenter network dedicated to this task, comprising core operational, data and laboratory centers, as well as research sites located worldwide in Africa (Malawi, South Africa, Tanzania, Uganda, Zambia and Zimbabwe), Asia (China, India and Thailand), Europe (Russia), South America (Peru) and the United States.
The National Institutes of Health announced the formation of the international HIV Prevention Trials Network to develop and test promising non-vaccine strategies to prevent the spread of HIV/AIDS. The global initiative will explore alternative measures, besides AIDS vaccines, that may be able to block or reduce infection with HIV. The network will constitute NIH's largest comprehensive multicenter network dedicated to this task, comprising core operational, data and laboratory centers, as well as research sites located worldwide in Africa (Malawi, South Africa, Tanzania, Uganda, Zambia and Zimbabwe), Asia (China, India and Thailand), Europe (Russia), South America (Peru) and the United States.
"We must investigate all potential strategies to stop HIV transmission, including microbicides and other biomedical and behavioral interventions," said Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases. "The HPTN strengthens our capability to discover new and better measures to protect people, especially children and women, from HIV infection."
The NIH also announced four public-private partnerships intended to accelerate development of promising HIV/AIDS vaccines for use around the world. The new partnerships, called HIV vaccine design and development teams, will tap the different skills and talents of private industry and academic research centers, and provide incentive to move HIV/AIDS vaccine candidates out of the laboratory and into human testing. NIAID has committed to spending approximately $70 million over the next five years on the four development team contracts that have been awarded to Advanced Bioscience Laboratories Inc., Kensington, MD; Chiron Corp., Emeryville, CA; University of New South Wales, Australia; and Wyeth Lederle Vaccines and Nutrition, Pearl River, NY.
"Many vaccines in use today resulted from both government-sponsored and private research," said Fauci. "The HVDDT program is a unique addition to this model that encourages the private sector to increase their AIDS vaccine efforts while allowing NIAID to work closely with its partners throughout the development process."
HVDDT awards are incentive-based contracts aimed at vaccine candidates in the middle of the development pipeline - those not yet in clinical testing. Applicants were required to describe a clear development plan, including timelines to indicate when different phases would be completed. Funding will be provided in increments as these preset milestones are reached. PR
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.